A trial fibrillation (AF) is a common arrhythmia 1,2 that is increasing in prevalence. 2 The incidence of AF increases with age 1 and is increased in patients with heart failure, left ventricular hypertrophy (LVH), coronary heart disease, and hypertension. [3][4][5][6][7] [8] [9] [10] [11] [12] [13] [14] The higher risk of death, [3][4][5] sudden cardiac death, 6 heart failure, 5 and stroke 3,7, 8 in patients with AF and the substantial risks associated with antithrombotic therapies aimed at decreasing the risk of embolic sequelae 15 make prevention of the development of new AF a major clinical and epidemiological goal.
A trial fibrillation (AF) is a common arrhythmia 1, 2 that is increasing in prevalence. 2 The incidence of AF increases with age 1 and is increased in patients with heart failure, left ventricular hypertrophy (LVH), coronary heart disease, and hypertension. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] The higher risk of death, [3] [4] [5] sudden cardiac death, 6 heart failure, 5 and stroke 3, 7, 8 in patients with AF and the substantial risks associated with antithrombotic therapies aimed at decreasing the risk of embolic sequelae 15 make prevention of the development of new AF a major clinical and epidemiological goal.
Hypertension is the most important risk factor for new AF, estimated to account for between 14% and 22% of the population-attributable risk 9, 11 ; AF risk is also related to the severity of hypertension. 8, 13, 14 Some, [16] [17] [18] but not all, studies 13 suggest that reductions in blood pressure (BP) can reduce the risk of developing new AF. Recent work found that even upper normal levels of systolic BP (SBP) were associated with an increased long-term risk of AF, 19 suggesting that more aggressive BP control may further decrease AF risk. More intensive antihypertensive treatment aimed at greater reduction of BP or a lower achieved pressure to further reduce cardiovascular risk has produced mixed outcomes 16, [20] [21] [22] [23] [24] and remains controversial. 25, 26 However, there are only limited data on whether achievement of a lower SBP during treatment of hypertension is associated with a decreased risk of AF. 14, 16 Therefore, the purpose of this study was to examine whether lower achieved SBP (≤130 mm Hg) is associated with a lower incidence of AF compared with typical SBP control (131-141 mm Hg) and less-adequate control (SBP ≥142 mm Hg) in hypertensive patients with ECG LVH, independent of treatment modality, baseline risk factors, in-treatment diastolic BP, and the previously demonstrated predictive value of in-treatment heart rate and regression of ECG LVH by Cornell product criteria for new AF in this population.
Methods
The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 3, 6, [27] [28] [29] [30] enrolled 9193 hypertensive patients with ECG LVH by Cornell voltage-duration product 31 or Sokolow-Lyon voltage criteria 32 on a screening ECG in a prospective, double-blind randomized study that compared cardiovascular morbidity and mortality with losartan-as opposed to atenolol-based treatment, 29 as previously described. 3, 6, [27] [28] [29] [30] A total of 362 patients had a history of AF (n=342) or AF on their LIFE baseline ECG (n=135), leaving 8831 patients without AF by history or baseline ECG in the present post hoc, retrospective analysis (4809 women and 4022 men; mean age, 67±7 years). Treatment regimens, 29 electrocardiographic methods, 6, [27] [28] [29] [30] [31] [32] and end point determination 27 have been discussed in detail previously and are outlined in detail in the online-only Data Supplement.
Data management and analyses were performed by the investigators using SPSS version 22.0 (IBM, Inc, Armonk, NY). Data are presented as mean±SD for continuous variables and proportions for categorical variables. Differences in mean values between patients grouped according to the development of new AF were compared using unpaired t tests; comparison of proportions between groups was performed using χ 2 tests. The relative predictive value for new-onset AF of in-treatment SBP ≤130 mm Hg and in-treatment SBP between 131 and 141 mm Hg was compared with that of in-treatment SBP ≥142 mm Hg using Cox proportional hazards models in which each SBP group was included as a time-varying covariate. Baseline risk factors and a treatment group indicator were entered as standard covariates, and incident myocardial infarction, incident heart failure, and in-treatment diastolic BP, Cornell product LVH, heart rate, and high-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol were entered as time-varying covariates. To illustrate the results of time-varying covariate analyses, new-onset AF rate over time was plotted as a function of changing in-treatment SBP group using a univariate modified Kaplan-Meier method, implemented in SAS Release 8.2 on the WIN_PRO platform. 33 Additional multivariable Cox analyses were performed in which hazard ratios for new-onset AF were calculated for 5-mm Hg decrements of in-treatment SBP, in which for each cutoff value AF risk was compared between patients with SBP at that level or lower and patients with SBP greater than that level. Adjusted hazard ratios were plotted versus in-treatment SBP. Finally, univariate and multivariable Cox models were performed in which AF risk was related to in-treatment SBP treated as a continuous variable, with hazard ratios calculated as a function of a lower SBP of 10 mm Hg. For all tests, a 2-tailed P value of <0.05 was required for statistical significance.
Results

Patient Characteristics in Relation to Development of AF
During mean follow-up of 4.6±1.1 years, new-onset AF occurred in 701 patients (7.9%). Clinical and demographic characteristics of patients in relationship with the development of new AF are shown in Table 1 . Hypertensive patients who developed new AF were older, more likely to be men, nonblack, have a history of ischemic heart disease, previous myocardial infarction, stroke and heart failure, had lower total cholesterol levels, greater albuminuria, and were less likely to be randomized to losartan-based treatment, but they were similar with respect to other baseline characteristics.
Blood pressure and ECG measurements at baseline and changes in these measurements between baseline and last instudy determination or the development of new-onset AF are shown in Table 2 . Patients with new-onset AF had slightly higher mean baseline SBP, lower baseline diastolic blood pressure, and greater reduction in SBP but similar change in diastolic blood pressure. New-onset AF was associated with slightly lower mean baseline heart rate, slightly longer QRS duration, and more severe baseline ECG LVH by Cornell product and Sokolow-Lyon voltage criteria. Patients who developed AF had smaller reduction in mean heart rate, slightly greater increase in QRS duration, and less regression of LVH by Cornell product criteria but had similar change in Sokolow-Lyon voltage compared with patients who did not develop AF.
New-Onset AF in Relation to In-Treatment SBP
The relationships of new-onset AF with in-treatment SBP are shown in Table 3 and Figure 1 . In univariate analyses, compared with in-treatment SBP ≥142 mm Hg, both in-treatment SBP between 131 and 141 mm Hg and in-treatment SBP ≤130 mm Hg entered as a time-varying covariates identified patients with statistically significant 46% lower risk of new-onset AF. In multivariable Cox analyses adjusting for baseline risk factors and randomized treatment as standard covariates and baseline and in-treatment diastolic BP, Cornell product LVH, heart rate, high-density lipoprotein cholesterol, and non-highdensity lipoprotein cholesterol as time-varying covariates, an in-treatment achieved SBP of 131 to 141 remained associated with a statistically significant 24% decreased risk of new AF and patients who achieved a SBP of ≤130 mm Hg had a 40% reduction in the risk of developing new AF compared with patients with in-treatment SBP ≥142 mm Hg (Table 3) .
Multivariable Cox analyses for prediction of new-onset AF were repeated using 5-mm Hg cutoff increments for in-treatment SBP (Figure 2) , demonstrating that the association of low achieved SBP with decreased new AF was not dependent on use of the 3 SBP groups used in this study. In these analyses, lower SBP down to a cutoff of ≤130 mm Hg remained associated with statistically significant decreased risk of new-onset AF and it was only at SBP levels of ≤125 mm Hg that lower SBP was no longer associated with a significantly reduced risk of AF ( Figure 2 ). Of note, in univariate and parallel multivariable Cox analyses in which SBP was entered as a continuous variable, with no assumptions on the threshold of SBP that might be associated with new AF, every 10-mm Hg decrease in SBP as a continuous variable was associated with 24% and 13% lower risks of new-onset AF, respectively. In addition, there were no significant interactions between the level of SBP achieved and age treated either as a continuous variable or partitioned at age 60 in these multivariable analyses.
Discussion
Previous studies have established a strong relationship between hypertension and development of AF 8, 9, 11 and that AF risk is proportional to the severity of hypertension. 8, 13, 14 Although, some, [16] [17] [18] but not all, 13 studies suggest that reductions in BP are associated with a reduced risk of AF, several studies have found that the increased risk of developing AF persists even into the upper normal range of BP, 17, 19 raising the attractive hypothesis that more aggressive BP control in hypertensive patients could further reduce AF risk compared with standard BP control. 34 More aggressive treatment of hypertension aimed at greater reduction of BP or a lower achieved BP to produce greater reduction of cardiovascular risk has had mixed results 16, [20] [21] [22] [23] [24] and remains controversial 25, 26 pending results of the ongoing Systolic Blood Pressure Intervention Trial (SPRINT). 35 To date, there are only limited and conflicting data on the relationship of AF to the degree of SBP control in hypertensive patients. 14, 16 In a case-controlled study of patients undergoing treatment for hypertension, 14 compared with a reference level of 120 to 129 mm Hg, both SBP ≥150 and SBP <120 were associated with an increased risk of incident AF in multivariable logistic regression models. However, patients and controls were only matched on the basis of age, sex, and index year of presentation, multivariate models did not take into account either previous myocardial infarction or heart failure, which could be variably related to pre-existing hypertension and independently contribute to the risk of new AF, and CI indicates confidence interval; HR, hazard ratio; and SBP, systolic blood pressure. *Adjusted for randomized treatment allocation, age, sex, race, diabetes mellitus, history of ischemic heart disease, myocardial infarction or heart failure, previous antihypertensive therapy, baseline serum glucose and creatinine, urine albumin/creatinine ratio, Sokolow-Lyon voltage and QRS duration entered as standard covariates and incident myocardial infarction, incident heart failure and baseline and in-treatment diastolic blood pressure, Cornell product left ventricular hypertrophy, heart rate, HDL, and non-HDL cholesterol entered as time-varying covariates. did not take into account time to incident AF. In contrast, in Cardio-Sis, 16 treatment to a more aggressive SBP target (<130 mm Hg) was associated with a significantly lower incidence of the secondary end point of new-onset AF than treatment to a less aggressive target SBP of <140 mm Hg (10/557, 1.8% versus 21/553, 3.8%; hazard ratio, 0.46; 95% confidence interval, 0.22-0.98; P=0.044) but with few cases of new AF.
This study extends these findings to a large and well-characterized population of hypertensive patients at substantially higher risk of developing new AF, demonstrating that achievement of a SBP of ≤130 mm Hg was associated with a decreased risk of incident AF, independent of standard AF risk factors and of the previously demonstrated relationship of AF risk to randomized treatment, 3 and in-treatment ECG LVH and heart rate in this population. 27, 28 Importantly, the decreased risk of new AF with lower achieved SBP persists after adjusting for both incident myocardial infarction and incident heart failure, which are independently associated with new AF and could also be associated with lower achieved SBP. Treating SBP as a timevarying covariate in these analyses in which the last SBP before the development of new AF is used in the Cox models further mitigates the potential for reverse causality in which new AF associated with either new myocardial infarction or heart failure could potentially further contribute to a lower a SBP by using the SBP measurement before development of AF and also adjusting for incident myocardial infarction or heart failure. Furthermore, previous analyses in the overall LIFE study population 23 demonstrated that an achieved SBP of ≤130 mm Hg was not associated with any increased risk of ischemic events, such as myocardial infarction or stroke. Analysis of risk of AF in relation to SBP over the full spectrum of measurements (Figure 2) demonstrates that the significantly decreased risk of new AF at lower achieved SBP levels is attenuated once achieved SBP is ≤125 mm Hg. These findings, the lower risk of AF at SBP <130 in the Cardio-Sis study 16 but the increased risk of AF found at SBP <120 in the case-control study, 14 suggest a target SBP of 120 to 129 mm Hg for future studies of this question.
There are many possible explanations for the relationship between lower SBP and decreased AF incidence. First, direct or indirect effects of SBP on left atrial (LA) remodeling could mediate the relationship of lower achieved SBP with reduced AF incidence. Less LA dilatation could be mediated indirectly via lower achieved BP reducing LV stiffness 36 or via a potentially greater regression of LVH with lower BP achieved and the previously demonstrated relationship of LA enlargement to ECG LVH over time. 37 However, the lower incidence of AF with lower achieved SBP in this study persisted even after controlling for the potential effect of changing ECG LVH over time, suggesting that this effect may be mediated by a hypertrophy-independent mechanism. Indeed, reversal of experimental LA volume overload in sheep can reverse abnormal electrophysiological LA remodeling, 38 even when hypertrophy persists. Similarly, either direct or indirect effects of lower achieved SBP on LA fibrosis could mediate the relationship with AF as the extent of LA fibrosis has been demonstrated to Hazard ratios for new-onset atrial fibrillation according to on-treatment systolic blood pressure by 5 mm Hg cutoff values, adjusted for the effects of treatment with losartan versus atenolol, age, sex, race, diabetes mellitus, history of ischemic heart disease, myocardial infarction or heart failure, previous antihypertensive therapy, baseline serum glucose and creatinine, urine albumin/creatinine ratio, Sokolow-Lyon voltage and QRS duration entered as standard covariates and incident myocardial infarction, incident heart failure and baseline and intreatment diastolic blood pressure, Cornell product left ventricular hypertrophy, heart rate, high-density lipoprotein cholesterol (HDL), and non-HDL cholesterol entered as time-varying covariates. No. at risk correlate with risk of AF recurrence after ablation therapy. 39 Further work is necessary to determine whether lower achieved SBP is independently associated with less LA enlargement and less regression of ECG LVH over time and whether changes in these anatomic and ECG measures are associated with corresponding prevention or reduced progression of LA electrophysiological and fibrotic substrate for AF. Several limitations of this study warrant review. First, this is a post hoc analysis of a previously conducted randomized clinical trial that did not randomize patients to different SBP control groups. This could lead to possible sources of confounding because of differences between the SBP groups both at baseline and during the trial. Although we control for known, measured differences between groups and for the possible effects of randomized treatment, incident heart failure and myocardial infarction and in-treatment diastolic BP, heart rate and ECG LVH on outcome, multivariable analyses may not fully adjust for these differences and cannot adjust for other potential factors that were not measured. As a consequence, whether low achieved SBP may be a marker of less extensive underlying structural or functional abnormalities that reduce the predisposition to AF cannot be definitively addressed using this approach. Second, the absence of data on LA size in the vast majority of patients and the small number of cases of incident AF in the echocardiographic substudy of LIFE who were free of AF at study baseline (n=70) preclude a meaningful evaluation of whether the relationship of SBP to incident AF could be in part explained by differences in LA size in patients who develop new AF as observed in the general LIFE echocardiographic substudy and other populations while in sinus rhythm. 40 Third, use of ECG LVH criteria to select patients for LIFE increased the baseline risk of the population, suggesting that caution should be used in generalizing these findings to hypertensive patients at lower risk. Finally, because incident AF was only ascertained on study ECGs and at study visits, 27 the possibility that cases of paroxysmal AF were missed cannot be excluded.
Perspectives
Given the increasing prevalence of AF 2 and the particularly strong association of AF with hypertension, 9,11 these findings have important implications for the treatment of high BP. Further study is necessary to determine whether targeting hypertensive patients without AF to lower BP goals can reduce the burden of AF in hypertensive patients and hence reduce the downstream consequences of AF, including increased stroke and heart failure risks. What Is New?
• In a group of patients with high blood pressure in whom a large enough number develop atrial fibrillation to allow meaningful analysis, achieving lower goals of systolic blood pressure was associated with a lower risk of developing atrial fibrillation than treating to more standard systolic blood pressure goals.
What Is Relevant?
• This study suggests that patients with high blood pressure at high risk of developing atrial fibrillation may benefit from more aggressive treatment to lower their blood pressure to decrease the risk of developing atrial fibrillation.
Summary
Further study is necessary to determine whether giving patients with high blood pressure more medications to lower their systolic blood pressure to a lower treatment goal can reduce atrial fibrillation without increasing the risk of other cardiovascular problems or side effects.
Treatment Regimens
Blinded treatment was begun with losartan 50 mg or atenolol 50 mg daily and matching placebo of the other agent, with a target pressure of 140/90 mm Hg or lower. During clinic visits at frequent intervals for the first 6 months and at 6 month intervals thereafter, study therapy could be up-titrated by addition of hydrochlorothiazide 12.5 mg, followed by increase in blinded losartan or atenolol to 100 mg daily. In patients whose BP was still not controlled, additional open-label upward titration of hydrochlorothiazide and if necessary institution of therapy with a calcium channel blocker or additional other medications (excluding AT1-or beta-blockers or ACE-inhibitors) was added to the double-blind treatment regimen (1). Electrocardiography Study ECGs were obtained at baseline, at 6-months and at yearly follow-up intervals until study termination or patient death and were interpreted as previously reported in detail (2-4). Cornell product >2,440 mm•msec or Sokolow-Lyon voltage >38 mm were used to identify LVH (1-7). Endpoint Determination New-onset AF was identified in a total of 701 patients, either from protocol-mandated instudy ECGs undergoing Minnesota coding at the ECG core lab (n=405) and/or by adverse event reports of AF by the investigators (n=572) (3). In patients who had new AF by both criteria, the earliest onset of AF was taken as the time to new AF for this analysis. Atrial flutter was not independently coded. [3, 6, [27] [28] [29] [30] 纳入9193例ECG LVH高血压患者，如 先前已描述的 [3, 6, [27] [28] [29] [30] ，采用Cor nell电压-持续时间乘积 [31] 或Sokolow-Lyon电压标准 [32] 筛选ECG，在前瞻性、随 机双盲试验设计中，比较氯沙坦治疗与阿替洛尔治疗对 高血压LVH患者心血管事件发病率和死亡率的影响 [29] 。 在目前的事后（post hoc）回顾性分析中，总计362例患
治疗后更低收缩压对高血压患者发生心房颤动风险的影响
有关治疗方案 [29] 、心电图方法 [6, [27] [28] [29] [30] [31] [32] 和终点的确定 [27] 过去 已作详述， 并在附录在线资料中进行概述。 
